Clinical Trial Update: To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing continued safety and adherence of the dapivirine vaginal ring in HIV-negative women has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Prevention

Drugs mentioned

• dapivirine vaginal ring (25 mg) (dapivirine)

Snippet

Sponsor: International Partnership for Microbicides, Inc. | Conditions: HIV Prevention | Phase 3 | Status: COMPLETED | Results posted: 2022-10-25